AlphaMadera's AlphaVal page classifies Viemed Healthcare, Inc. as a Platform & Compounding FCF business and values it using Two-stage FCF DCF, then compares the result to the current market price to flag VMD as undervalued, fairly valued, or overvalued.

What is Viemed Healthcare, Inc.'s fair value?

Fair value for VMD comes from a Two-stage FCF DCF model -- the approach AlphaVal selected for this company's Platform & Compounding FCF classification. The live AlphaVal page shows bear, base, and bull scenarios alongside the key assumption behind each.

How does AlphaMadera value VMD?

AlphaVal routes each company to one of ten valuation archetypes based on its business model. VMD was classified as Platform & Compounding FCF and is valued using Two-stage FCF DCF, built from VMD's most recent reported fundamentals.

VMD - Viemed Healthcare, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $14.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 85% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Overvalued Strong

Trading 95.6% above fair value

Current Price $9.80

Bear Case $3.12 68.2% downside ($3.12 - $9.80) / $9.80 = -68.2% 9% stage 1 growth, 11% discount

Fair Value $5.01 48.9% downside ($5.01 - $9.80) / $9.80 = -48.9% 16% stage 1 growth, 11% discount

Bull Case $7.14 27.1% downside ($7.14 - $9.80) / $9.80 = -27.1% 20% stage 1 growth, 11% discount

Adjust Assumptions

DCF Stage 1 Growth Rate

15.5%

Discount Rate (WACC)

11.0%

Terminal Growth Rate

3.0%

Key Value Driver

FCF growth rate (16% base case)

Terminal Value % of EV 43%

Implied Market Multiple 63.5x

Market is pricing in (growth) 24.4% vs our 15.5% base

Plain-Language Summary

Using a two-stage FCF DCF with 16% growth decelerating over 15 years, discounted at 11%, the base-case intrinsic value is $5.01 per share.

Warnings

⚠ Stock-based employee pay equals 61% of profits. This dilutes existing shareholders, so cash flow alone overstates what owners really earn.

Key Risks

P/E alone misleads — earnings depressed by growth investment
Cyclical or commodity businesses may be misclassified as platforms
Terminal value dominance suggests sensitivity to long-run assumptions